Transplant-lite

Induction of graft-versus-malignancy using fludarabine- based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies

Issa F. Khouri, Michael Keating, Martin Körbling, Donna Przepiorka, Paolo Anderlini, Susan O'Brien, Sergio Giralt, Cindy Ippoliti, Brigitte Von Wolff, James Gajewski, Michelle Donato, David Claxton, Naoto Ueno, Borje Andersson, Adrian Gee, Richard Champlin

Research output: Contribution to journalArticle

826 Citations (Scopus)

Abstract

Purpose: To investigate the use of a nonmyeloablative fludarabine-based preparative regimen to produce sufficient immunosuppression to allow engraftment of allogeneic stem cells and induction of graft-versus- leukemia/lymphoma (GVL) as the primary treatment modality for patients with chronic lymphocytic leukemia (CLL) and lymphoma. Patients and Methods: Fifteen patients were studied. Six patients were in advanced refractory relapse, and induction therapy had failed in two patients. Patients with CLL or low-grade lymphoma received fludarabine 90 to 150 mg/m2 and cyclophosphamide 900 to 2,000 mg/m2. Patients with intermediate-grade lymphoma or in Richter's transformation received cisplatin 25 mg/m2 daily for 4 days; fludarabine 30 mg/m2; and cytarabine 500 mg/m2 daily for 2 days. Chemotherapy was followed by allogeneic stem-cell infusion from HLA- identical siblings. Patients with residual malignant cells or mixed chimerism could receive a donor lymphocyte infusion of 0.5 to 2 x 108 mononuclear cells/kg 2 to 3 months posttransplantation if graft-versus-host disease (GVHD) was not present. Results: Eleven patients had engraftment of donor cells, and the remaining four patients promptly recovered autologous hematopoiesis. Eight of 11 patients achieved a complete response (CR). Five of six patients (83.3%) with chemosensitive disease continue to be alive compared with two of nine patients (22.2%) who had refractory or untested disease at the time of study entry (P = .04). Conclusion: These findings indicate the feasibility of allogeneic hematopoietic transplantation with a nonablative preparative regimen to produce engraftment and GVL against lymphoid malignancies. The ability to induce remissions with donor lymphocyte infusion in patients with CLL, Richter's, and low-grade and intermediate- grade lymphoma is direct evidence of GVL activity against these diseases. This approach appears to be most promising in patients with chemotherapy- responsive disease and low tumor burden.

Original languageEnglish (US)
Pages (from-to)2817-2824
Number of pages8
JournalJournal of Clinical Oncology
Volume16
Issue number8
StatePublished - Aug 1998
Externally publishedYes

Fingerprint

Cell Transplantation
Blood Cells
Stem Cells
Transplants
Drug Therapy
Neoplasms
B-Cell Chronic Lymphocytic Leukemia
Therapeutics
Non-Hodgkin's Lymphoma
Lymphoma
Leukemia
fludarabine
Tissue Donors
Lymphocytes
Chimerism
Aptitude
Time and Motion Studies
Cytarabine
Homologous Transplantation
Hematopoiesis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Transplant-lite : Induction of graft-versus-malignancy using fludarabine- based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. / Khouri, Issa F.; Keating, Michael; Körbling, Martin; Przepiorka, Donna; Anderlini, Paolo; O'Brien, Susan; Giralt, Sergio; Ippoliti, Cindy; Von Wolff, Brigitte; Gajewski, James; Donato, Michelle; Claxton, David; Ueno, Naoto; Andersson, Borje; Gee, Adrian; Champlin, Richard.

In: Journal of Clinical Oncology, Vol. 16, No. 8, 08.1998, p. 2817-2824.

Research output: Contribution to journalArticle

Khouri, IF, Keating, M, Körbling, M, Przepiorka, D, Anderlini, P, O'Brien, S, Giralt, S, Ippoliti, C, Von Wolff, B, Gajewski, J, Donato, M, Claxton, D, Ueno, N, Andersson, B, Gee, A & Champlin, R 1998, 'Transplant-lite: Induction of graft-versus-malignancy using fludarabine- based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies', Journal of Clinical Oncology, vol. 16, no. 8, pp. 2817-2824.
Khouri, Issa F. ; Keating, Michael ; Körbling, Martin ; Przepiorka, Donna ; Anderlini, Paolo ; O'Brien, Susan ; Giralt, Sergio ; Ippoliti, Cindy ; Von Wolff, Brigitte ; Gajewski, James ; Donato, Michelle ; Claxton, David ; Ueno, Naoto ; Andersson, Borje ; Gee, Adrian ; Champlin, Richard. / Transplant-lite : Induction of graft-versus-malignancy using fludarabine- based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. In: Journal of Clinical Oncology. 1998 ; Vol. 16, No. 8. pp. 2817-2824.
@article{40d04fbbc9414d9491293c05856f4e3a,
title = "Transplant-lite: Induction of graft-versus-malignancy using fludarabine- based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies",
abstract = "Purpose: To investigate the use of a nonmyeloablative fludarabine-based preparative regimen to produce sufficient immunosuppression to allow engraftment of allogeneic stem cells and induction of graft-versus- leukemia/lymphoma (GVL) as the primary treatment modality for patients with chronic lymphocytic leukemia (CLL) and lymphoma. Patients and Methods: Fifteen patients were studied. Six patients were in advanced refractory relapse, and induction therapy had failed in two patients. Patients with CLL or low-grade lymphoma received fludarabine 90 to 150 mg/m2 and cyclophosphamide 900 to 2,000 mg/m2. Patients with intermediate-grade lymphoma or in Richter's transformation received cisplatin 25 mg/m2 daily for 4 days; fludarabine 30 mg/m2; and cytarabine 500 mg/m2 daily for 2 days. Chemotherapy was followed by allogeneic stem-cell infusion from HLA- identical siblings. Patients with residual malignant cells or mixed chimerism could receive a donor lymphocyte infusion of 0.5 to 2 x 108 mononuclear cells/kg 2 to 3 months posttransplantation if graft-versus-host disease (GVHD) was not present. Results: Eleven patients had engraftment of donor cells, and the remaining four patients promptly recovered autologous hematopoiesis. Eight of 11 patients achieved a complete response (CR). Five of six patients (83.3{\%}) with chemosensitive disease continue to be alive compared with two of nine patients (22.2{\%}) who had refractory or untested disease at the time of study entry (P = .04). Conclusion: These findings indicate the feasibility of allogeneic hematopoietic transplantation with a nonablative preparative regimen to produce engraftment and GVL against lymphoid malignancies. The ability to induce remissions with donor lymphocyte infusion in patients with CLL, Richter's, and low-grade and intermediate- grade lymphoma is direct evidence of GVL activity against these diseases. This approach appears to be most promising in patients with chemotherapy- responsive disease and low tumor burden.",
author = "Khouri, {Issa F.} and Michael Keating and Martin K{\"o}rbling and Donna Przepiorka and Paolo Anderlini and Susan O'Brien and Sergio Giralt and Cindy Ippoliti and {Von Wolff}, Brigitte and James Gajewski and Michelle Donato and David Claxton and Naoto Ueno and Borje Andersson and Adrian Gee and Richard Champlin",
year = "1998",
month = "8",
language = "English (US)",
volume = "16",
pages = "2817--2824",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "8",

}

TY - JOUR

T1 - Transplant-lite

T2 - Induction of graft-versus-malignancy using fludarabine- based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies

AU - Khouri, Issa F.

AU - Keating, Michael

AU - Körbling, Martin

AU - Przepiorka, Donna

AU - Anderlini, Paolo

AU - O'Brien, Susan

AU - Giralt, Sergio

AU - Ippoliti, Cindy

AU - Von Wolff, Brigitte

AU - Gajewski, James

AU - Donato, Michelle

AU - Claxton, David

AU - Ueno, Naoto

AU - Andersson, Borje

AU - Gee, Adrian

AU - Champlin, Richard

PY - 1998/8

Y1 - 1998/8

N2 - Purpose: To investigate the use of a nonmyeloablative fludarabine-based preparative regimen to produce sufficient immunosuppression to allow engraftment of allogeneic stem cells and induction of graft-versus- leukemia/lymphoma (GVL) as the primary treatment modality for patients with chronic lymphocytic leukemia (CLL) and lymphoma. Patients and Methods: Fifteen patients were studied. Six patients were in advanced refractory relapse, and induction therapy had failed in two patients. Patients with CLL or low-grade lymphoma received fludarabine 90 to 150 mg/m2 and cyclophosphamide 900 to 2,000 mg/m2. Patients with intermediate-grade lymphoma or in Richter's transformation received cisplatin 25 mg/m2 daily for 4 days; fludarabine 30 mg/m2; and cytarabine 500 mg/m2 daily for 2 days. Chemotherapy was followed by allogeneic stem-cell infusion from HLA- identical siblings. Patients with residual malignant cells or mixed chimerism could receive a donor lymphocyte infusion of 0.5 to 2 x 108 mononuclear cells/kg 2 to 3 months posttransplantation if graft-versus-host disease (GVHD) was not present. Results: Eleven patients had engraftment of donor cells, and the remaining four patients promptly recovered autologous hematopoiesis. Eight of 11 patients achieved a complete response (CR). Five of six patients (83.3%) with chemosensitive disease continue to be alive compared with two of nine patients (22.2%) who had refractory or untested disease at the time of study entry (P = .04). Conclusion: These findings indicate the feasibility of allogeneic hematopoietic transplantation with a nonablative preparative regimen to produce engraftment and GVL against lymphoid malignancies. The ability to induce remissions with donor lymphocyte infusion in patients with CLL, Richter's, and low-grade and intermediate- grade lymphoma is direct evidence of GVL activity against these diseases. This approach appears to be most promising in patients with chemotherapy- responsive disease and low tumor burden.

AB - Purpose: To investigate the use of a nonmyeloablative fludarabine-based preparative regimen to produce sufficient immunosuppression to allow engraftment of allogeneic stem cells and induction of graft-versus- leukemia/lymphoma (GVL) as the primary treatment modality for patients with chronic lymphocytic leukemia (CLL) and lymphoma. Patients and Methods: Fifteen patients were studied. Six patients were in advanced refractory relapse, and induction therapy had failed in two patients. Patients with CLL or low-grade lymphoma received fludarabine 90 to 150 mg/m2 and cyclophosphamide 900 to 2,000 mg/m2. Patients with intermediate-grade lymphoma or in Richter's transformation received cisplatin 25 mg/m2 daily for 4 days; fludarabine 30 mg/m2; and cytarabine 500 mg/m2 daily for 2 days. Chemotherapy was followed by allogeneic stem-cell infusion from HLA- identical siblings. Patients with residual malignant cells or mixed chimerism could receive a donor lymphocyte infusion of 0.5 to 2 x 108 mononuclear cells/kg 2 to 3 months posttransplantation if graft-versus-host disease (GVHD) was not present. Results: Eleven patients had engraftment of donor cells, and the remaining four patients promptly recovered autologous hematopoiesis. Eight of 11 patients achieved a complete response (CR). Five of six patients (83.3%) with chemosensitive disease continue to be alive compared with two of nine patients (22.2%) who had refractory or untested disease at the time of study entry (P = .04). Conclusion: These findings indicate the feasibility of allogeneic hematopoietic transplantation with a nonablative preparative regimen to produce engraftment and GVL against lymphoid malignancies. The ability to induce remissions with donor lymphocyte infusion in patients with CLL, Richter's, and low-grade and intermediate- grade lymphoma is direct evidence of GVL activity against these diseases. This approach appears to be most promising in patients with chemotherapy- responsive disease and low tumor burden.

UR - http://www.scopus.com/inward/record.url?scp=0031879197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031879197&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 2817

EP - 2824

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 8

ER -